Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

main

lifesciences-yale-ocs-stem-phd-pathways-navigating-career-paths

Join Yale OCS on Feb 28, 2025, for a hybrid event on IP careers for STEM PhDs & postdocs, featuring Dr. Miho Kaneko, Patent Attorney at Goodwin.

Yale OCS STEM PhD Pathways: Navigating Career Paths in Patent Law with Miho Kaneko

Summary

Speakers

Miho Kaneko

Related Content

HyClone Seeks to Quash Amgen’s Subpoena Issued in Denosumab BPCIA Litigation Against Fresenius

EU Biosimilar Regulatory and Launch Updates

BioNTech Acquires Biotheus To Boost Oncology Strategy

Medtech M&A and VC Signal Positive Momentum Entering 2025

Federal Circuit Affirms Injunction Against Samsung and Formycon in Aflibercept BPCIA Litigation

FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar

Preparing for EDGAR Next – New Requirements for All EDGAR Filers

FDA Publishes Its First Draft Guidance On Use of Artificial Intelligence in the Development of Drugs and Biological Products

Anthos Therapeutics To Be Acquired by Novartis For Up To $3.1 Billion

Goodwin Paris Recognized by Chambers France 2025

Goodwin Rare Disease Symposium 2025

Goodwin Advises Akero Therapeutics on the Closing of its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Advised Aclarion on the $4.7 Million Closing of Registered Direct Offering of Common Stock

Goodwin Expands Antitrust Litigation Offering with the Arrival of Partner Alexandra Russell in Washington, D.C.

Goodwin Advises Underwriters in Metsera’s $275 Million Initial Public Offering

Goodwin Advises Royalty Pharma on $511 Million Sale of Morphosys Development Funding Bonds

Life Sciences